[Adamantiadi-Behçet syndrome: treatment with recombinant leukocytic interferon].
OBJECTIVE
To evaluate efficacy of synthetic leukocytic interferon (SLI) in patients with severe Adamantiadi-Behçet syndrome (ABS).


METHODS
The trial enrolled 18 patients (11 men and 7 women aged 25 to 43 years) with severe ABS. The duration of the disease ranged from 1 to 12 years. Subcutaneous ABS injections in a dose 5 x 10(6) U/m2 for 8 weeks followed by 3 x 10(6) for 16 weeks. The results were estimated by standard clinical and biochemical indices.


RESULTS
All 18 patients responded to the treatment. After the course of treatment 13 patients were in remission for 4-52 months. The rest of the patients were given one more course of treatment.
Kacunaros
M
M
Alicanidu
O
O
Balacucas
D
D
Agapakis
D
D
Palyaleksis
K
K
Karali
V
V
Kukurikos
S
S
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011994:Recombinant Proteins; D013997:Time Factors
D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins
Sindrom Adamantiadi-Bekhcheta: lechenie rekombinantnym leĭkotsitarnym interferonom.